Report: Elanco, Bayer Deal Could Come Soon

Posted: Updated:
(Image courtesy of Elanco) (Image courtesy of Elanco)

A new report from Bloomberg says an agreement between Greenfield-based Elanco Animal Health Inc. (NYSE: ELAN) and Germany-based Bayer AG could be announced as soon as next week. The news service reported Wednesday the two companies are looking to announce a deal involving Bayer's animal health unit around the time of Elanco's earnings release, which will take place Tuesday.

Bloomberg, citing sources who asked to not be identified due to the private nature of the discussions between the two companies, says Elanco plans to use stock to pay for at least part of the acquisition. One source told the news service Bayer would get a "significant minority stake" in Elanco and the companies are currently working out potential antitrust issues.

Discussions of a possible merger between the two companies were first reported in July. Bloomberg previously reported the sale of Bayer's animal health unit could be valued at as much as $9 billion.

A spokesperson for Elanco declined to comment on the story. The company has made several acquisitions over the years, including last month when it completed its $245 million acquisition of Kansas-based Aratana Therapeutics. Last week, Elanco announced plans to acquire Montreal-based Prevtech Microbia Inc. in a $60 million deal.

Elanco was also involved in a massive deal in 2014 when its then-parent company, Indianapolis-based Eli Lilly and Co. (NYSE: LLY), acquired the animal health unit of Novartis AG for $5.4 billion.

Elanco was spun off from Lilly into its own publicly-traded company last year.

  • Perspectives

    • Circling Back on WeWork

      Back in July when we first discussed WeWork, this fast-growing but money-losing venture was one of the most talked-about IPOs in years. At that time, we noted that it was too early to say what would happen, but “it should be very interesting to watch it all play out.” Turns out, that was a massive understatement!



Company Name:
Confirm Email:
INside Edge
Morning Briefing
BigWigs & New Gigs
Life Sciences Indiana
Indiana Connections


  • Most Popular Stories

    • Photo courtesy of MutualBank

      MutualBank President Dies

      The President and Chief Operating Officer of Muncie-based MutalBank Pat Botts has died. In a statement on Facebook posted Sunday, the company said the passing was unexpected.

    • Artist rendering of proposed headquarters for Ruoff Home Mortgage in Fort Wayne.

      Ruoff to Build New HQ in Downtown Fort Wayne

      Fort Wayne-based Ruoff Home Mortgage has announced plans to build a $43 million corporate headquarters in downtown Fort Wayne. Plans call for a 110-thousand square foot, nine-story structure, at the corner of Ewing Street and Jefferson Boulevard. The building would include leasable office and retail space, as well as a parking garage. It would overlook Parkview Field, home of the Fort Wayne Tin Caps minor league baseball team. The company is currently located on...

    • Photo courtesy of Indiana Premium outlets

      Simon Announces New Name for Shopping Center

      Indianapolis-based Simon Property Group Inc. (NYSE: SPG) has announced Edinburgh Premium Outlets will become Indiana Premium Outlets. The company says extensive enhancements are currently underway to reflect the new name and are slated for completion by Holiday 2019. 

    • (image provided by Purdue University)

      'PlaneEnglish' Technology Lands U.S. Air Force Funding

      Technology intended to help young pilots learn how to better communicate with air traffic controllers has caught the attention of the United States Air Force and earned the two Purdue University graduates, who developed the software, a $50,000 federal grant. The creators of the simulator technology PlaneEnglish have been awarded a Small Business Innovation Research award. 

    • FDA Approves Lilly Migraine Drug

      The U.S. Food and Drug Administration has given another approval for a drug from Indianapolis-based Eli Lilly and Co. (NYSE: LLY). The approval of REYVOW is for the treatment of patients with acute migraines.